In this randomized trial of more than 9300 subjects with T2DM and high cardiovascular risk, liraglutide was seen to decrease the incidence of the composite cardiovascular primary endpoint (occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) compared with placebo (13.0 and 14.9% in the liraglutide and placebo group, respectively
Among these therapies, Tesamorelin has emerged as a standout option, offering unique benefits not only for weight loss but also for overall health
Safety Disclaimer The content on this page is provided for informational and educational purposes only and should not be interpreted as medical advice, diagnosis, or treatment
You must wait the full 30 to 60 minutes before having your first cup of joe
Hsia DS, Grove O, Cefalu WT